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Objective. There is evidence of a negative association between diabetes and abdominal aortic aneurysm (AAA). The aim of
this study was to assess whether there is a similar relationship between both diabetes and glucose level, and infra-renal
aortic diameter throughout its range.
Design and methods. Infra-renal aortic diameter was measured using ultrasound in 12,203 men aged 65e83 years as
part of a trial of screening for AAA. A range of cardiovascular risk factors were also assessed. In a follow-up study, fasting
serum glucose was measured in 2,859 non-diabetic men. Aortic diameter was logarithmically transformed and treated as
both a continuous and categorical variable in stepwise multivariate linear and logistic models.
Results. The median aortic diameter was slightly smaller in the diabetic men (21.3 3.9 vs 21.6 3.8, P< 0.0001). There
was an independent negative association between diabetes and AAA (OR 0.79, 95% CI: 0.63,0.98), and an inverse corre-
lation (Coefficient: 0.0064, p¼ 0.0024) between fasting glucose and aortic diameter in non-diabetic men.
Conclusions. Diabetes is inversely associated with both AAA and aortic diameter in men over 65 years. This association is
independent of other risk factors for AAA. Aortic diameter also has an inverse relationship with fasting glucose concen-
trations in men without diabetes.
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Cross-sectional data from several screening studies in-
dicate that diabetes is protective against abdominal
aortic aneurysms (AAAs). The earliest observation
of this negative association (odds ratio (OR) 0.78,
95% CI: 0.62, 0.98) was that published by LaMorte
et al. in 1995.1 Soon after this, in an initial report
from a large-scale study of screening (n¼ 73,451),
Lederle et al. noted an ‘unexpected’ significant nega-
tive association between diabetes and AAA (OR 0.68).2
This observation was considered to be an artifact
until confirmed in a second cohort of 52,745 subjects
studied by the same group (OR 0.60).3 A separate
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supportive evidence.4 In addition, a study of diabetic
men >60 years of age found the prevalence of AAAs
to be only 2.3%, a figure less than half that in men of
the same age in the general population.5
As diabetes is positively associated with most
forms of vascular disease, the negative association
with AAAs is seemingly paradoxical. It is not known
whether there is a negative relationship between
diabetes and increasing aortic diameter below the
aneurysmal range (<30 mm) or whether there is any
association between aortic diameter and glycaemia.
The present study assessed the relationship between
both diabetes and non-diabetic serum glucose concen-
trations and infra-renal aortic diameter across its
whole range in a large cohort of men aged over 65
years who participated in a trial of screening for
AAAs.rved.
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Recruitment and baseline assessment of subjects
Details of the Western Australian trial of AAA screen-
ing are described elsewhere.6,7 Briefly, between April
1996 and January 1999, eligible men were identified
and recruited from the electoral roll, and invited to at-
tend a screening clinic. On arrival at the clinic, the trial
was explained to each participant and written consent
was obtained. Each man completed a risk factor ques-
tionnaire covering aspects of medical history and life-
style relevant to cardiovascular disease (CVD)6 before
a nurse measured height, weight, hip and waist cir-
cumference, and blood pressure. The maximum dia-
meter of the infra-renal aorta was measured using
a Toshiba Capasee ultrasound machine with a
3 .75 M Hz probe (Toshiba Australia, North Ryde,
NSW). In addition to the data from the questionnaire,
the Western Australian Data Linkage System8 was
used to identify men with any admissions to hospital
for CVD (including AAA) or diabetes prior to screen-
ing. These admissions were identified using the relevant
diagnosis and procedure codes from the International
Classification of Diseases (ICD). This system was also
used to identify deaths and admissions to hospital
after baseline screening. The relevant Institutional
Ethics Committees approved the study protocol.
Follow-up study
After screening, follow-up of all men identified to
have large AAAs (>50 mm) was arranged by the rel-
evant General Practitioner. Men with aortic diameters
in the range 30e50 mm participated in a separate study
of expansion of small AAAs.9 Between November
2001 and August 2004 all surviving men from the orig-
inal cohort were invited to participate in a follow-up
study which included another questionnaire and
measurement of fasting serum glucose.
Statistical methods
Analyses were performed using SAS v9.1.10 Because
the distribution of aortic diameter was positively
skewed, we performed logarithmic transformation
and treated the transformed diameter as both a contin-
uous and categorical variable. Age, blood pressure,
and body mass index (BMI) were incorporated in
analysis as continuous variables. A diagnosis of dia-
betes was based on i) self-reported history of, or
current treatment for, diabetes, or ii) a fasting serum
glucose >7.0 mmol/L at follow-up. This was validatedEur J Vasc Endovasc Surg Vol 33, May 2007by checking hospital admissions for diabetes (ICD-9
codes: 250.0e250.9). In diabetic men, duration of dia-
betes was categorised into quartiles (2 yr, n¼ 411;
3e5 yr, n¼ 287; 6e12 yr, n¼ 335; >13 yr, n¼ 308).
The remaining variables were dichotomous or cate-
gorical. We tested for differences in normally distrib-
uted variables using t-tests and used the Wilcoxon
median scores test for aortic diameter, duration of di-
abetes and glucose. The Pearson Chi-square test was
used for categorical variables. A two-tailed p-value
of <0.05 was used throughout.
We used stepwise multivariate linear models to as-
sess the association between diabetes and infra-renal
aortic diameter and, in non-diabetic men, between
serum glucose and diameter. To determine whether
the relationship between aortic diameter and diabetes
applied to individuals with non-aneurysmal aortas,
we also examined the associations for diameters
<30 mm and 30 mm separately. Stepwise multi-
variate logistic regression was used to assess the fol-
lowing: the association between diabetes and the
presence of an AAA in all men; and between the du-
ration of diabetes and AAA in diabetic men; and
whether the relationship between diabetes (or serum
glucose level in non-diabetic men) and diameter was
graded. In categorical analyses aortic diameter was di-
vided into intervals (10e18 mm, 19e22 mm, 23e29 mm
and 30 mm) based on standard deviations of logarith-
mic diameter.11 The number of individuals and events
was sufficient in these intervals to have the power
to detect meaningful differences in risk. Adjusted
estimates of risk and corresponding 95% confidence
intervals (CIs) were derived for each interval. We re-
peated this procedure to assess the association, in
non-diabetic men, between fasting serum glucose
and aortic diameter. Glucose concentration was di-
vided into quartiles (<5.1; 5.1e5.4; 5.41e5.9; >5.9
mmol/L) and a concentration above the lowest quar-
tile was used as a variable in the multivariate logistic
regression on an empirical basis. In order to adjust for
minor changes in aortic diameter that may have oc-
curred between baseline screening and the measure-
ment of glucose concentration an analysis based on
growth rates of small AAAs12 was also undertaken.
This did not produce substantial difference in the
results (data not shown).
Results
The baseline and follow-up cohorts are summarised
in Fig. 1. Of the 12,203 men attending initial screening,
2,379 (19.5%) died before the follow-up survey and
4,233 (42.5%) attended follow-up and underwent
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(n=12,203)
No follow-up (n=7,970)
• Died before follow-up (n=2,379)
• Did not participate (n=3,890) 
• Completed questionnaire only 
(n=1,701)
Attended follow-up
blood testing
(n=4,233)
(n=2,859)
Follow-up Analysis 
Excluded (n=1,374) 
• Not fasted (n=916)
• Diabetes: self reported 
diabetes (n=407) or 
glucose level > 7.0 mmol/L
(n=51) 
Baseline Analysis (n=12,203)
• Diabetes (n=1,453) 
• No diabetes (n=10,750) 
Fig. 1. A summary of the cohorts. The ‘Baseline Analysis’ uses diabetes as the risk factor of interest; the ‘Follow-up Analysis’
uses fasting serum glucose concentration in non-diabetic men as the risk factor of interest.venous blood sampling. Of the men who fasted over-
night (n¼ 3,317), 2,859 (86.2%) were not known to
have diabetes. Of these men, 51 had fasting serum
glucose >7.0 mmol/L and were re-classified as dia-
betic. Comparing all relevant subgroups (those at-
tending vs not attending; fasting vs not fasting; no
diabetes vs diabetes) revealed little difference in any
variables at baseline - in particular there was no dif-
ference in hypertension (history of, admission for or
treated for hypertension) or dyslipidaemia (history
of or treated for ‘high cholesterol’).
The characteristics of the 12,203 men who partici-
pated in the initial screening for AAA are shown in
Table 1. The frequency of self-reported diabetes
in men with and without AAAs was similar (11.1%
vs 12.2%, p¼ 0.4). Amongst diabetic men (n¼ 1,453),
the median (inter-quartile range) duration of diabetes
was significantly longer in those without AAA (5
(10.0) vs 3 (8.0) years, p¼ 0.002). The median aortic
diameter was slightly smaller in the diabetic men
(21.3 3.9 vs 21.6 3.8, p< 0.0001). The difference
appeared to be due to a greater likelihood of aortic
diameters in the smallest interval (10e18 mm) in the
diabetic group (Fig. 2).In linear modelling, for any given diameter, the
presence of diabetes was associated with a reduction
in aortic diameter of 2.21% (95% CI: 3.17% to 1.16%)
irrespective of other risk factors. Table 2 summarises
the multivariate logistic modelling of risk factors for
AAAs (aortic diameter 30 mm). There was an inde-
pendent negative association between diabetes and
AAA (OR 0.79, 95% CI 0.63 to 0.98). In an analysis
of diabetic men only, using duration of diabetes
of 2 years as the reference, there was evidence of
decreasing risk of AAA with increasing quartiles of
duration of diabetes: 3e5 years OR 0.50 (95% CI
0.27, 0.89), 6e12 years OR 0.57 (95% CI 0.33, 0.97),
>12 years OR 0.37 (95% CI 0.19, 0.70). Using an aortic
diameter <18 mm as the reference, there was evidence
of a graded inverse relationship between diabetes and
increasing aortic diameter interval (Table 3). In this
model, a man with diabetes was 33% less likely to
have an AAA than a small (<18 mm) aorta.
The same pattern existed for fasting serum glucose
and aortic diameter in men without diabetes (Table 3).
A fasting serum glucose above the lowest quartile
(>5.1 mmol/L) was associated with a halving of the
likelihood of an AAA compared with a smallEur J Vasc Endovasc Surg Vol 33, May 2007
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cient: 0.0064, P¼ 0.0024) between fasting serum glu-
cose in this group and aortic diameter is shown in
Fig. 3. This relationship was also present (correlation
coefficient: 0.0024, P¼ 0.0027) for aortic diameters
in the non-aneurysmal range (<30 mm).
Table 1. Characteristics of 12,203 men attending baseline screening
Variables No AAA (11,270) AAA (933) p value
Age, years 71.6 4.3 72.9 4.3 <0.0001
Body Mass Index, kg/m2 26.8 3.7 27.1 3.8 0.0289
Place of birth
(Mediterranean), %
10.1 5.9 <0.0001
Aortic diameter, mm 21.7 2.6 37.1 9.0 <0.0001
Systolic blood
pressure, mmHg
146.4 19.9 141.4 19.1 <0.0001
Diastolic blood
pressure, mmHg
73.9 8.9 72.8 9.4 0.021
Smoking, % never 30.3 13.5 <0.0001
Ex smoker 59.5 67.2 <0.0001
Current smoker
<25 cigs/day
8.5 15.4 <0.0001
Current smoker
25 cigs/day
1.7 3.9 <0.0001
History of CVD, % 42.3 61.9 <0.0001
Hypertension, % 43.0 55.9 <0.0001
Dyslipidaemia, % 35.0 45.1 <0.0001
Diabetes 12.2 11.1 0.40
At least one parent had
AAA, %
1.6 2.6 0.008
At least one sibling had
AAA, %
2.6 4.9 <0.0001
Vigorous exercise, % 24.8 18. <0.0001
Aortic diameter represented with median and interquartile range,
and the Wilcoxon Median Scores test used to compare differences.
All other continuous variables represented as mean SDs and
differences compared with t-tests. The Pearson Chisquare test was
used for categorical variables. History of CVD includes coronary,
cerebrovascular, peripheral and mesenteric artery disease.
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Fig. 2. Prevalence of diabetes among men in different inter-
vals of aortic diameter at baseline (n¼ 12,203).Eur J Vasc Endovasc Surg Vol 33, May 2007Discussion
The present study confirms earlier reports that diabe-
tes is apparently protective against AAAs in elderly
men.3,4 We have extended previous observations to
show that this relationship exists across a continuum
of aortic diameters that includes the non-aneurysmal
range. Furthermore, fasting serum glucose level in
non-diabetic men also has an inverse relationship
with aortic diameter. These various associations are
independent of other variables associated with aortic
diameter.
The main strength of the present study is that it
utilises a large, well-characterised, community-based
cohort. Limitations include using self-report as the
basis of a diagnosis of diabetes (although, where pos-
sible, validation using hospital morbidity data was
undertaken), and the fact that fasting serum glucose
levels were only measured at follow-up rather than
at the time aortic diameter was determined. Neverthe-
less, analysis of the relationship between serum glu-
cose and diameter was confined to men who did not
have diabetes at follow-up and who were therefore
free of diabetes at the time the diameter was mea-
sured. Furthermore, an analysis based on corrected
aortic diameter which adjusted for predicted change
between the time of screening and the point where se-
rum glucose was measured did not produce different
results.
The cause of the negative association between dia-
betes and aortic diameter remains to be established. It
presumably arises from glycaemia-associated altera-
tions in vascular matrix which protect against the
formation of AAAs. Our observation that men with
diabetes for the longest duration were least at risk of
an AAA, raises the possibility of progressive constric-
tive remodelling. It is well known that the walls of
Table 2. Multivariate logistic regression of risk factors for abdom-
inal aortic aneurysm (aortic diameter 30 mm) at baseline
(n[ 12,203)
Odds Ratio (95% CI)
Age, per 1 year 1.09 (1.07,1.11)
BMI (kg/m2) 1.03 (1.01,1.05)
Place of Birth (Mediterranean) 0.57 (0.42,0.75)
Smoking (ever) 2.04 (1.84,2.26)
Systolic blood pressure, per 1 mmHg 0.99 (0.98,0.99)
Diastolic blood pressure, per 1 mmHg 1.03 (1.02,1.04)
History of CVD 1.83 (1.58,2.12)
Hypertension 1.47 (1.27,1.71)
Dyslipidaemia 1.42 (1.22,1.65)
Diabetes 0.79 (0.63,0.98)
At least one parent had AAA 1.88 (1.17,2.89)
At least one sibling had AAA 1.81 (1.17,2.89)
Vigorous exercise 0.78 (0.65,0.93)
603Aortic Diameter and GlycaemiaTable 3. Dose-response relationship between diabetes, and fasting glucose (in non-diabetic men), and intervals of aortic diameter,
adjusted for variables in Table 1
Aortic diameter, mm (N)
Baseline Analysis 10e18 (952) 19e22 (6,520) 23e29 (3,798) 30e95 (933)
Diabetes Odds ratio (95% CI) 1.00 (1.00,1.00) 0.74 (0.61,0.90) 0.65 (0.53,0.81) 0.64 (0.47,0.86)
Follow-up Analysis 16e18 (188) 19e22 (1,615) 23e29 (863) 30e70 (193)
Fasting Glucose above the lowest quartile Odds ratio (95% CI) 1.00 (1.00,1.00) 0.85 (0.59,1.21) 0.69 (0.47,0.99) 0.52 (0.31,0.88)aneurysmal aortas show evidence of up-regulated pro-
teolytic activity and accelerated matrix depletion.13,14
By contrast, diabetes is characterized by increased
matrix deposition due to a combination of increased
synthesis and reduced proteolysis.15 In vitro studies
have shown that a high glucose concentration acceler-
ates synthesis of collagen.16,17 Diabetes is also
associated with the deposition of advanced glycation
endproducts (AGEs) which form non-enzymic cross-
links that involve both collagen and elastin.18,19
Matrix re-modelling and proteolysis is impaired by
this glycation.20
Another possible explanation for the negative asso-
ciation between diameter and diabetes may involve
homocysteine (Hcy). Elevated levels of Hcy have
been implicated in the pathogenesis of AAAs.21 Al-
though levels of Hcy eventually rise in diabetic indi-
viduals as glomerular filtration rate declines, levels
in pre-diabetic states and early in the course of type
2 diabetes may be lower than normal due to
hyperfiltration.22,23
Evidence that both diabetes and glucose concentra-
tion have an inverse relationship with aortic diameter
does not assist in the immediate management of
AAAs. The observation does suggest however, that
conditions favourable to decreased proteolysis and
Glucose = -0.0064Diameter + 5.5176
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Fig. 3. The relationship between fasting serum glucose
(measured at follow-up, n¼ 2,859) in men without diabetes
and aortic diameter.increased matrix formation may protect against
AAA formation. This justifies the on-going search
for pharmacological treatment of small AAAs.
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